In Brief: Inhaled corticosteroids
Inhaled corticosteroids: FDA broadens indications of inhaled corticosteroids in asthma treatment to read "indicated in the maintenance treatment of asthma as prophylactic therapy....Also indicated for asthma patients who require systemic corticosteroid administration where adding [the inhaled corticosteroid] may reduce or eliminate the need for systemic corticosteroids." The inhaled compounds are "not indicated for the relief of acute bronchospasm." Inhaled corticosteroids previously were indicated as second-line treatment after bronchodilators. Products affected by the labeling change include Forest's Aerobid, Rhone-Poulenc Rorer's Azmacort, Glaxo Wellcome's Beclovent, Astra's Rhinocort and Schering-Plough's Vanceril...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth